This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).
Study Type
OBSERVATIONAL
Enrollment
480
Administration by intravitreal injection
Many locations
Multiple Locations, Japan
RECRUITINGThe number of participants with adverse events (AEs)
Time frame: Up to 6 months
Intraocular Pressure (IOP) value after study drug administration
In case of transient and/or persistent IOP elevation
Time frame: Up to 6 months
Mean changes in Visual Acuity
Time frame: Up to 6 months
Proportion of participants with improvement of anterior neovascularization
Time frame: Up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.